PEG-PLA nanoparticles as carriers for nasal vaccine delivery.
This report presents an overview of the potential of nanoparticles as nasal carriers for drug/vaccine administration. In addition, this report shows, for the first time, the efficacy of polylactic acid nanoparticles coated with a hydrophilic polyethyleneglycol coating (PEG-PLA nanoparticles) as carriers for the nasal transport of bioactive compounds. For this purpose, tetanus toxoid (TT), a high molecular weight protein (Mw 150,000 Da), was chosen as a model antigen and encapsulated in the PEG-PLA nano- and microparticles (200 nm and 1.5 microm respectively). These nanosystems were first characterized for their stability in the presence of lysozyme and also for their size, electrical charge, loading efficiency, in vitro release of antigenically active toxoid and afterwards, these formulations were administered intranasally to mice and the systemic and mucosal anti-tetanus responses were evaluated for up to 24 weeks. Additionally, PEG-PLA particles labeled with rhodamine 6G were administered intranasally to rats in order to visualize their interaction with the nasal mucosae by fluorescence microscopy. Their behavior was compared with that of the well known PLA nanoparticles (200 nm). The results showed that PLA nanoparticles suffered an immediate aggregation upon incubation with lysozyme, whereas the PEG-coated nanoparticles remained totally stable. The antibody levels elicited following i.n. administration of PEG-coated nanoparticles were significantly higher than those corresponding to PLA nanoparticles. Furthermore, PEG-PLA nanoparticles generated an increasing and a long lasting response. The qualitative fluorescence microscopy studies revealed that PEG-PLA particles are able to cross the rat nasal epithelium. These studies indicate that the PEG coating around the particles has a role in stabilizing PLA particles in mucosal fluids and that it facilitates the transport of the nanoencapsulated antigen, hence eliciting a high and long lasting immune response.
Vila
A
A
Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, Santiago de Compostela, Spain.
Sánchez
A
A
Evora
C
C
Soriano
I
I
Vila Jato
J L
JL
Alonso
M J
MJ
D000281:Administration, Intranasal; D000818:Animals; D001682:Biological Availability; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers; D004797:Enzyme-Linked Immunosorbent Assay; D007114:Immunization / Q000379:methods; D051379:Mice; D008856:Microscopy, Fluorescence; D023421:Models, Animal; D010316:Particle Size; D010533:Peritoneal Lavage; D011092:Polyethylene Glycols / Q000494:pharmacology*; D051381:Rats; D012463:Saliva / Q000737:chemistry; D012680:Sensitivity and Specificity; D013745:Tetanus Toxoid / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D014018:Tissue Distribution; D014612:Vaccines / Q000008:administration & dosage
D004337:Drug Carriers; D013745:Tetanus Toxoid; D014612:Vaccines; D011092:Polyethylene Glycols